

Ref: FOI/GS/ID 8353

Please reply to: FOI Administrator Trust Management Maidstone Hospital Hermitage Lane Maidstone, Kent

ME16 9QQ

Email: mtw-tr.foiadmin@nhs.net

www.mtw.nhs.uk

27 July 2023

## Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to Urothelial and Colorectal Cancer.

## You asked:

- 1. In the past 3 months, how many patients have been treated for urothelial cancer with the following agents?
- a. Avelumab
- b. Atezolizumab
- c. Carboplatin with Gemcitabine
- d. Carboplatin single or in any other combination
- e. Cisplatin with Gemcitabine
- f. Cisplatin single or in any other combination
- g. Nivolumab
- h. Pembrolizumab
- i. Any other systemic anti-cancer therapy
- j. Palliative care only
- 2. Does your trust participate in any ongoing clinical trials for the treatment of urothelial cancer? If so, can you please provide the name of each trial along with the number of patients taking part?
- 3. In the past 3 months, how many patients have been treated for colorectal cancer [CRC] with the following agents?
- a. Aflibercept
- b. Bevacizumab
- c. Capecitabine
- d. CAPIRI

- e. CAPOX (XELOX)
  f. Cetuximab in combination with FOLFIRI/FOLFOX
  g. Cetuximab not in combination with FOLFIRI or FOLFOX
  h. Irinotecan only
  i. FOLFIRI
  j. FOLFOX
  k. Fluorouracil (5FU) only
- I. Oxaliplatin only
- m. Nivolumab
- n. Panitumumab in combination with FOLFIRI/FOLFOX
- o. Panitumumab not in combination with FOLFIRI or FOLFOX
- p. Pembrolizumab
- q. Raltitrexed
- r. Ramucirumab
- s. Regorafenib
- t. Tegafur + Uracil
- u. Any other systemic anti-cancer therapy
- v. Palliative care only

## Trust response:

- 1.
- a. 4
- b. 4
- c. 6
- d. 0
- e. 2
- f. 0
- g. 1
- h. 0
- i. 0
- j. 0
- 2. ATLANTIS An adaptive multi-arm phase II trial of maintenance targeted therapy after chemotherapy in metastatic urothelial cancer (IRAS 186191) Open to recruitment 10 patients recruited
- 3.
- a. 0
- b. 0
- c. 33
- d. 10
- e. 16
- f. 11
- g. 6
- h. 0
- i. 29
- j. 20
- k. 2
- I. 0
- m. 1

- n.
- ο.
- p.
- q. r.
- s.
- 3 4 6 4 0 3 0 15 t. u.
- ٧.